ArticleBlood cancer journal2022

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.

Shady Adnan Awad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.